Literature DB >> 24010974

Effect of symptomatic pseudomeningocele on improvement in pain, disability, and quality of life following suboccipital decompression for adult Chiari malformation type I.

Scott L Parker1, Saniya S Godil, Scott L Zuckerman, Stephen K Mendenhall, Noel B Tulipan, Matthew J McGirt.   

Abstract

OBJECT: Suboccipital decompression is a common procedure for patients with Chiari malformation Type I (CMI). Published studies have reported complication rates ranging from 3% to 40%, with pseudomeningocele being one of the most common complications. To date, there are no studies assessing the effect of this complication on long-term outcome. Therefore, the authors set out to assess the effect of symptomatic pseudomeningocele on patient outcomes following suboccipital decompression for CM-I.
METHODS: The study comprised 50 adult patients with CM-I who underwent suboccipital craniectomy and C-1 laminectomy with or without duraplasty. Clinical presentation, radiological studies, operative variables, and complications were assessed for each case. Baseline and 1-year postoperative patient-reported outcomes were assessed to determine improvement in pain, disability, and quality of life. The extent of improvement was compared for patients with and without development of a postoperative symptomatic pseudomeningocele.
RESULTS: A symptomatic pseudomeningocele developed postoperatively in 9 patients (18%). There was no difference with regard to clinical, radiological, or operative variables for patients with or without a postoperative pseudomeningocele. Patients without a pseudomeningocele had significant improvement in all 9 patient-reported outcome measures assessed. On the other hand, patients with pseudomeningocele only had significant improvement in headache (as measured on the Numeric Rating Scale) and headache-related disability (as measured on the Headache Disability Index) but no improvement in quality of life. Twenty-nine (71%) of 41 patients without a pseudomeningocele reported improvement in health status postoperatively compared with only 3 (33%) of 9 patients with a postoperative pseudomeningocele (p = 0.05).
CONCLUSIONS: Surgical management of CM-I in adults provides significant and sustained improvement in pain, disability, general health, and quality of life. Development of a postoperative symptomatic pseudomeningocele has lingering effects at 1 year, and it significantly diminishes the overall benefit of suboccipital decompression for CM-related symptoms. Further research is needed to accurately predict which patients may benefit from decompression alone without duraplasty.

Entities:  

Mesh:

Year:  2013        PMID: 24010974     DOI: 10.3171/2013.8.JNS122106

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

1.  Development of Common Data Elements for Use in Chiari Malformation Type I Clinical Research: An NIH/NINDS Project.

Authors:  Mark G Luciano; Ulrich Batzdorf; Roger W Kula; Brandon G Rocque; Cormac O Maher; John Heiss; Bryn A Martin; Paolo A Bolognese; Allison Ashley-Koch; David Limbrick; Dorothy J Poppe; Kaitlyn M Esposito; Joanne Odenkirchen; Joy R Esterlitz; Sherita Ala'i; Kristen Joseph; Robin S Feldman; Robert Riddle
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

2.  Outcomes and complications for individual neurosurgeons for the treatment of Chiari I malformation at a children's hospital.

Authors:  Tasha-Kay Walker-Palmer; D Douglas Cochrane; Ashutosh Singhal; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2019-05-24       Impact factor: 1.475

3.  Pseudomeningocele formation following chiari decompression: 19-year retrospective review of predisposing and prognostic factors.

Authors:  R Menger; D E Connor; M Hefner; G Caldito; A Nanda
Journal:  Surg Neurol Int       Date:  2015-05-07

4.  Significance of Pseudomeningocele After Decompressive Surgery for Chiari I Malformation.

Authors:  Artur Balasa; Przemysław Kunert; Mateusz Bielecki; Sławomir Kujawski; Andrzej Marchel
Journal:  Front Surg       Date:  2022-05-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.